CA-PROSIMO
Prosimo, the Application Experience Infrastructure company, is demonstrating (Booth #511) its full-stack solution for simplifying multi-cloud networking at Gartner IT Infrastructure Operations & Cloud Strategies conference, taking place December 6-8th in Las Vegas. The company plans to present a customer case example of the advantages of using a single network infrastructure for its cloud computing services.
The Gartner Market Guide for Multicloud Networking Software encourages I&O leaders responsible for cloud and edge infrastructure to “prefer the native capabilities of the cloud providers when starting out, and avoid forklifting data center networking designs and vendors in the public cloud, because this will lead to integration and cost inefficiencies.”1 And to “invest in MCNS when a consistent set of broader, “full-stack” Level 3 through Level 7 networking and network security capabilities (e.g., routing, DNS, CDN, WAF, firewall, and observability) via a single management platform, across multiple providers, is needed.”
The Prosimo Full stack meets the criteria of leading Fortune 100 companies and large enterprises and in our opinion aligns with the recommendations of leading analysts. Enterprise customers can now quickly build multi-cloud architectures with a single, unified platform from Prosimo. With support for hybrid cloud deployments, customers can instantiate any service from any cloud provider, such as Amazon Web Services (AWS), Microsoft Azure, Google Cloud Platform (GCP), and others, without managing multiple environments.
Prosimo will exhibit and will share an example of how a single architecture can simplify cloud networking and demonstrate how Full Stack Transit enables companies to overcome multi-cloud complexity with business outcomes in sight.
Session Details:
During the show, Mehul Patel, Head of Marketing, Customer Insights, and Intelligence, will share how a Fortune 100 company accelerated its cloud journey:
Prosimo: One Arch = Simple Cloud Networking- Customer Case Study
Thursday, December 08, 2022 / 01:40 PM - 02:00 PM PST
Exhibit Showcase Theatre 1
Enterprises want to be successful with their cloud journey but need consistent architecture to connect into IaaS, PaaS, cloud-native services, and application endpoints. Neither DIY nor legacy networking approaches work due to complexity leading to unreliable infrastructure & high costs. Building a service networking highway that keeps applications in the center of the universe helps operate the infrastructure at the speed of applications. During this session, we’ll discuss how Fortune 100 companies are simplifying multicloud networking to accelerate their cloud journey achieving to up to 90% improvement in time-to-value, 99% application reliability, 60% savings in cloud spend, and 80% reduction in mean-time-to-resolution (MTTR) for faster positive business outcomes.
Resources
Connect with Prosimo
About the Gartner IT Infrastructure, Operations & Cloud Strategies Conference
The Gartner IT Infrastructure, Operations & Cloud Strategies Conference focuses on key topics for infrastructure and operations (I&O) leaders, including how to embrace change and serve evolving enterprise needs through optimizing workloads, maximizing efficiency, and building resilient systems and teams.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. While Gartner is hosting the Gartner Conference, Gartner is not in any way affiliated with Exhibiting Company or this promotion, the selection of winners or the distribution of prizes. Gartner disclaims all responsibility for any claims that may arise hereunder.
About Prosimo:
Prosimo delivers a simplified multicloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have adopted Prosimo to successfully roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst, WRVI Capital, and Blackrock. For more information, visit https://www.prosimo.io.
_______________________
1 Gartner, Market Guide for Cloud Networking Software, Andrew Lerner, Arun Chandrasekaran, Joe and Jonathan Forest, 12 April 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom